Cepheid Places 125 GeneXperts in Q3, Sees First Impact of PCR Royalty Expirations on Bottom Line
November 04, 2010
Cepheid Places 125 GeneXperts in Q3, Sees First Impact of PCR Royalty Expirations on Bottom Line
The company's third-quarter financial report shows "the first benefits from the phase-out of the very heavy royalty burden that we have carried since the launch of the GeneXpert back in 2006," said Cepheid CEO John Bishop.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Cepheid Says it Shipped Six GeneXpert Infinity Systems in Q3; Most Running '24 Hours a Day'
December 10, 2009 / PCR Insider - Cepheid Reports Q4, FY '12 Revenue Growth, but Looks to Address Issues from 'Challenging' Year
January 31, 2013 / PCR Insider - At JP Morgan, Cepheid, Gen-Probe, BD Tout Automated Instruments, Expanding Test Menus
January 21, 2010 / PCR Insider - Q&A: UK Hospitals Find Cepheid's Xpert MRSA Test at Point of Care Can Shave Hours Off Time-to-Result
December 10, 2009 / PCR Insider - Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent
April 25, 2013 / PCR Insider